Literature DB >> 11344382

Rifampicin pharmacokinetics with and without ciprofloxacin.

O E Orisakwe1, P U Agbasi, O J Afonne, S I Ofoefule, E Obi, C N Orish.   

Abstract

We investigated the effect of ciprofloxacin on rifampicin pharmacokinetics in five healthy subjects. Each subject received 600 mg rifampicin with 350 mL of water, and in the second phase, each subject received 600 mg rifampicin plus 500 mg ciprofloxacin with 350 mL of water. In each of the two phases, plasma rifampicin levels were measured from 1 to 24 hours. Treatment with ciprofloxacin significantly increased the half-life and also significantly decreased the maximum peak concentration of rifampicin. Area under the curve time for peak plasma concentration and volume of distribution were not significantly affected. In this study, we found that ciprofloxacin increases the half-life and reduces the maximum concentration of rifampicin in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344382     DOI: 10.1097/00045391-200105000-00003

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

1.  Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

Authors:  J N Suresh Kumar; Prameela Devi; Lakshmi Narasu; Ramesh Mullangi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

2.  Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Authors:  K E Stott; H Pertinez; M G G Sturkenboom; M J Boeree; R Aarnoutse; G Ramachandran; A Requena-Méndez; C Peloquin; C F N Koegelenberg; J W C Alffenaar; R Ruslami; A Tostmann; S Swaminathan; H McIlleron; G Davies
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

3.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.